CSL (ASX:CSL) share price falls amid ongoing AstraZeneca uncertainty

The CSL (ASX:CSL) share price is slumping today as ongoing uncertainty over the side effects of the AstraZeneca vaccine continue.

| More on:
falling healthcare asx share price Mesoblast capital raising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares are edging lower today as ongoing uncertainty over the side effects of the AstraZeneca COVID-19 vaccine continues. At the time of writing, the CSL share price is trading 0.11% lower at $265.22.

CSL is involved in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The company advised late last month it is set to produce more than 1 million doses of the AstraZeneca vaccine per week. 

It was commissioned by the government to produce 50 million doses of the AstraZeneca vaccine, before the vaccine was found to create a one-in-200,000 chance of blood clots – termed thrombosis with thrombocytopenia – around the brain and abdomen.

This led to the government's health body ruling out use of the vaccine for anyone under 50-years-old, including frontline health workers, but that uncertainty has led to the widespread cancellation of vaccine appointments across the country.

One Australian patient suffered thrombosis and a low platelet count after being vaccinated on 22 March.

The government has ordered an additional 20 million doses of the Pfizer vaccine, bringing the total to 40 million, which are due to arrive late this year.

This is leading to concerns that many of the vaccine doses CSL is producing will go to waste. Furthermore, the government has now thrown out any timeframe around rolling out the vaccine.

CSL said in a statement on 8 April that it was still committed to producing the AstraZeneca vaccine.

 "[CSL is] committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines."

"We will continue our focused and important efforts to manufacture this vaccine which remains critical for the protection of our most vulnerable populations."

CSL share price snapshot

Despite initial dips in the CSL share price as vaccine targets were changed and AstraZeneca uncertainty pervaded news headlines, the company's shares have continued to rise over the past month.

At the time of writing, the CSL share price is up by 0.74% this week and 3.66% over the past month.

However, it's worth noting that the company's shares have been slipping since the outbreak of the COVID-19 pandemic. Over the past 12 months, the CSL share price has lost around 19% and it's down around 12% against the healthcare sector during that same period.

Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »